Global Central Precocious Puberty (CPP) Treatment Market, By Type (Medication, Surgery), Diagnosis (Blood tests, MRI, CT scans, X-rays), Month (1-Month, 2-Month, 6-Month, Others), Route of Administration (Parenteral, Implants, Oral, Others), Gender (Girls, Boys), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029.
Market Analysis and Size
In recent years, the central precocious puberty (CPP) treatment market is anticipated to grow rapidly during the forecast period. Gonadotropin-releasing hormone (GnRH) agonists may be used to treat CPP because they block the stimulating effects of endogenous GnRH and speed up bone development, preventing early puberty. Menarche is delayed when GnRH treatment is used to delay the onset of puberty. Triptodor, Lupron Depot-Ped (leuprolide acetate), and Supprelin LA (histrelin acetate) are three approved therapy drugs for central precocious puberty currently on the market (CPP).
Data Bridge Market Research analyses that the central precocious puberty (CPP) treatment market was valued at USD 1,482.52 million in 2021 and is expected to reach USD 2,663.78 million by 2029, registering a CAGR of 7.60% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Gonadotropin-dependent precocious puberty is referred to as central precocious puberty (CPP). It's an endocrine-related developmental disorder marked by the beginning of pubertal changes, secondary sexual traits, faster growth, and bone maturation before the typical puberty age (8 years in girls and 9 years in boys). This is an idiopathic disorder. However, mutations in the MKRN3 gene are the most common known genetic cause of central precocious puberty.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Medication, Surgery), Diagnosis (Blood tests, MRI, CT scans, X-rays), Month (1-Month, 2-Month, 6-Month, Others), Route of Administration (Parenteral, Implants, Oral, Others), Gender (Girls, Boys), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), AbbVie Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Ireland), Ipsen Pharma (France), Arbor Pharmaceuticals (US), Tolmar Pharmaceuticals, Inc. (US), GP Pharm (Spain), Debiopharm (Switzerland), DAEWOONG PHARMACEUTICAL CO.,LTD (South Korea), Sun Pharmaceutical Industries Ltd. (India), Takeda Pharmaceutical Company Limited (Japan), Endo International plc (Ireland), AstraZeneca (UK), Johnson & Johnson Private Limited (US)
|
|
Market Opportunities
|
|
Central Precocious Puberty (CPP) Treatment Market Dynamics
Drivers
- Increasing prevalence of hormonal disorders
The rising prevalence of hormonal disorders is estimated to influence the market's growth rate. Along with this, the growing incidences of obesity will influence the market dynamics during the forecast period.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of central precocious puberty (CPP) treatment market is the rising healthcare expenditure which helps in improving its infrastructure.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the central precocious puberty (CPP) treatment market. Additionally, high disposable income and increase in the demand for disease-specific treatments will result in the expansion of central precocious puberty (CPP) treatment market. Along with this, rising use of radiation or chemotherapy for treating cancer and sedentary lifestyle of people will enhance the market's growth rate.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for growth in the central precocious puberty (CPP) treatment market. Along with this, rising drug approvals and launches will further propel the market's growth rate.
Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the central precocious puberty (CPP) treatment market growth during the forecast period.
Restraints/Challenges
On the other hand, the high cost associated with the treatment will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the central precocious puberty (CPP) treatment market. Additionally, a decline in clinical visits due to COVID-19 outbreak and lack of awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This central precocious puberty (CPP) treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the central precocious puberty (CPP) treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
One in every 5,000 to 10,000 girls suffers from central precocious puberty. Although the prevalence of the illness is unclear in boys, it is less prevalent in boys.
Central precocious puberty (CPP) treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Central Precocious Puberty (CPP) Treatment Market
The COVID-19 outbreak and subsequent lockdown in different nations had an impact on enterprises in all areas, including private healthcare. Due to heavy lockdown in certain places, the COVID-19 pandemic had disrupted the whole healthcare supply chain. The COVID-19 outbreak has had a three-fold influence on the economy of different countries worldwide: directly influencing production and demand, disrupting distribution routes, and having a financial impact on corporations and financial markets. Due to a decline in the supply of raw materials and pharmaceutical medications by manufacturing businesses linked with central precocious puberty, the impact of the COVID-19 pandemic is likely to hinder the growth of the global central precocious puberty market during the forecast period.
Global Central Precocious Puberty (CPP) Treatment Market Scope
The central precocious puberty (CPP) treatment market is segmented on the basis of type, month, route of administration, gender, diagnosis, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Medication
Long-acting Analogs of Gnrh (Gonadotrophin-Releasing Hormones)
- Leuprolide Acetate
- Triptoreline
- Histrelin Acetate
- Others
Adjunctive Treatments
- Surgery
Diagnosis
- Blood tests
- MRI
- CT scans
- X-rays
Month
- 1-Month
- 2-Month
- 6-Month
- Others
Route of Administration
- Parenteral
Subcutaneous
Intramuscular
Others
- Implants
- Oral
- Others
Gender
- Girls
- Boys
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Central Precocious Puberty (CPP) Treatment Market Regional Analysis/Insights
The Central precocious puberty (CPP) treatment market is analysed and market size insights and trends are provided by country, type, month, route of administration, gender, diagnosis, end-users and distribution channel as referenced above.
The countries covered in the Central precocious puberty (CPP) treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the central precocious puberty (CPP) treatment market because of the well-established healthcare infrastructure in this region. Additionally, growing focus of major key players on novel technology will further propel the market's growth rate in this region.
Asia-Pacific are expected to grow during the forecast period of 2022 to 2029 due to growing incidences of obesity and rising healthcare expenditure in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Central Precocious Puberty (CPP) Treatment Market Share Analysis
The Central precocious puberty (CPP) treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to central precocious puberty (CPP) treatment market.
Some of the major players operating in the central precocious puberty (CPP) treatment market are:
- Sanofi (France)
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Novartis AG (Switzerland)
- AbbVie Inc. (US)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (US)
- Teva Pharmaceutical Industries Ltd.(Ireland)
- Ipsen Pharma (France)
- Arbor Pharmaceuticals (US)
- Tolmar Pharmaceuticals, Inc. (US)
- GP Pharm (Spain)
- Debiopharm (Switzerland)
- DAEWOONG PHARMACEUTICAL CO.,LTD (South Korea)
- Sun Pharmaceutical Industries Ltd. (India)
- Takeda Pharmaceutical Company Limited (Japan)
- Endo International plc (Ireland)
- AstraZeneca (UK)
- Johnson & Johnson Private Limited (US)
SKU-